Clinical Trials Related to Prostate Cancer

Related studies linked through entity extraction aliases.

Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy

Status: COMPLETED
Phase: PHASE2

Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer

Status: COMPLETED
Phase: PHASE1/PHASE2

Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate

Status: COMPLETED
Phase: PHASE2

Calcitriol and Dexamethasone Before Radical Prostatectomy in Treating Patients With Localized Adenocarcinoma (Cancer) of the Prostate

Status: TERMINATED
Phase: PHASE2

Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008

Status: COMPLETED
Phase: PHASE2

Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer

Status: WITHDRAWN
Phase: PHASE2

Intensity-Modulated Radiation Therapy With or Without Decreased Radiation Dose to Erectile Tissue in Treating Patients With Stage II Prostate Cancer

Status: COMPLETED
Phase: NA

Computed Tomography (CT) Scans Using CT-On-Rails™ to Pinpoint the Location of the Tumor in Treating Patients With Prostate Cancer

Status: COMPLETED
Phase: PHASE1/PHASE2

Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate

Status: COMPLETED
Phase: PHASE2

Single-Dose Local Radiation Therapy Compared With Ibandronate in Treating Patients With Localized Metastatic Bone Pain

Status: COMPLETED
Phase: PHASE3

Behavior-Based Dietary Intervention in Treating Patients With Hormone-Refractory Prostate Cancer

Status: COMPLETED
Phase: PHASE1

Magnetic Resonance Imaging to Locate and Characterize Prostate Cancer

Status: COMPLETED
Phase: NA

Study of CEP-701 in Treatment of Prostate Cancer

Status: COMPLETED
Phase: PHASE2

Radiolabeled Monoclonal Antibody in Treating Patients With Progressive Metastatic Androgen-Independent Adenocarcinoma (Cancer) of the Prostate

Status: COMPLETED
Phase: PHASE2

Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases

Status: COMPLETED
Phase: PHASE2

Nerve-Sparing Radical Prostatectomy With or Without Nerve Grafting Followed by Standard Therapy for Erectile Dysfunction in Treating Patients With Localized Prostate Cancer

Status: COMPLETED
Phase: PHASE2

Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases

Status: TERMINATED
Phase: PHASE2

Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases

Status: COMPLETED
Phase: PHASE2

Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases

Status: COMPLETED
Phase: PHASE3

Soy Isoflavones in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage I or Stage II Adenocarcinoma of the Prostate

Status: COMPLETED
Phase: PHASE2